Mostrar el registro sencillo del ítem
dc.contributor.author
Navarro, Liliana Miriam
dc.contributor.author
Camprubí, Daniel
dc.contributor.author
Requena Méndez, Ana
dc.contributor.author
Buonfrate, Dora
dc.contributor.author
Giorli, Giovanni
dc.contributor.author
Kamgno, Joseph
dc.contributor.author
Gardon, Jacques
dc.contributor.author
Boussinesq, Michel
dc.contributor.author
Muñoz, Jose
dc.contributor.author
Krolewiecki, Alejandro Javier
dc.date.available
2021-03-16T19:00:38Z
dc.date.issued
2020-04
dc.identifier.citation
Navarro, Liliana Miriam; Camprubí, Daniel; Requena Méndez, Ana; Buonfrate, Dora; Giorli, Giovanni; et al.; Safety of high-dose ivermectin: A systematic review and meta-analysis; Oxford University Press; Journal of Antimicrobial Chemotherapy; 75; 4; 4-2020; 827-834
dc.identifier.issn
0305-7453
dc.identifier.uri
http://hdl.handle.net/11336/128418
dc.description.abstract
Background: Ivermectin is a key anthelmintic for the control of neglected tropical diseases. The main indications for population-level control with ivermectin through mass drug administration are onchocerciasis and lymphatic filariasis; however, there is interest in using higher, fixed-dose regimens for the control of scabies, soil-transmitted helminths and malaria. Safety data for these higher-dose regimens are needed. Methods: A systematic literature review and meta-analysis on the safety and doses of ivermectin was conducted. Eligible studies reported patient-level data and, for the meta-analysis, clinical trials reporting data on doses ≥200 and ≥400μg/kg were included. Incidence ratios were used to compare adverse events by severity and organ system affected. Results: The systematic search identified six studies for inclusion, revealing no differences in the number of individuals experiencing adverse events. A descriptive analysis of these clinical trials for a variety of indications showed no difference in the severity of the adverse events between standard (up to 400 ng/kg) and higher doses of ivermectin. Organ system involvement only showed an increase in ocular events in the higher-dose group in one trial for the treatment of onchocerciasis, all of them transient and mild to moderate in intensity. Conclusions: Although within this review the safety of high-dose ivermectin appears to be comparable to standard doses, there are not enough data to support a recommendation for its use in higher-than-approved doses. Ocular adverse events, despite being transient, are of concern in onchocerciasis patients. These data can inform programme managers and guide operational research activities as new approaches for the use of ivermectin are evaluated.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Oxford University Press
dc.rights
info:eu-repo/semantics/restrictedAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject
IVERMECTIN
dc.subject
SAFETY
dc.subject
HIGH DOSE
dc.subject
NEGLECTED TROPICAL DISEASES
dc.subject
ANTIPARASITARY
dc.subject
META-ANALYSIS
dc.subject.classification
Enfermedades Infecciosas
dc.subject.classification
Ciencias de la Salud
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
dc.title
Safety of high-dose ivermectin: A systematic review and meta-analysis
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2021-03-05T18:33:02Z
dc.identifier.eissn
1460-2091
dc.journal.volume
75
dc.journal.number
4
dc.journal.pagination
827-834
dc.journal.pais
Reino Unido
dc.journal.ciudad
Oxford
dc.description.fil
Fil: Navarro, Liliana Miriam. Universidad de Miguel Hernández; España
dc.description.fil
Fil: Camprubí, Daniel. Universidad de Barcelona; España
dc.description.fil
Fil: Requena Méndez, Ana. Universidad de Barcelona; España
dc.description.fil
Fil: Buonfrate, Dora. Istituto di Ricovero e Cura a Carattere Scientifico. Sacro Cuore Don Calabria Hospital. Tropical Diseases and Microbiology. Department of Infectious; Italia
dc.description.fil
Fil: Giorli, Giovanni. Istituto di Ricovero e Cura a Carattere Scientifico. Sacro Cuore Don Calabria Hospital. Tropical Diseases and Microbiology. Department of Infectious; Italia
dc.description.fil
Fil: Kamgno, Joseph. Centre de Recherche sur les Filarioses et autres Maladies tropicales; Camerún
dc.description.fil
Fil: Gardon, Jacques. Institut de Recherche Pour Le Developpement.; Francia
dc.description.fil
Fil: Boussinesq, Michel. Institut de Recherche Pour Le Developpement.; Francia
dc.description.fil
Fil: Muñoz, Jose. Universidad de Barcelona; España
dc.description.fil
Fil: Krolewiecki, Alejandro Javier. Universidad de Barcelona; España. Universidad Nacional de Salta. Sede Regional Orán. Instituto de Investigación de Enfermedades Tropicales; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Salta; Argentina
dc.journal.title
Journal of Antimicrobial Chemotherapy
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1093/jac/dkz524
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://academic.oup.com/jac/article-abstract/75/4/827/5710696?redirectedFrom=fulltext
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.scienceopen.com/document?vid=18b22778-054f-4a5f-b639-ea40f434dc30
Archivos asociados